1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) Program (NIH, CDC, FDA) (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This omnibus solicitation encourages small businesses to submit applications for projects that align with the missions of the participating NIH, CDC, and FDA institutes and centers.
Assistive technologies and software that improve health and save lives are within scope. This program provides non-dilutive funding for early-stage research and development.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses that meet SBA's eligibility criteria. Applicants for NIMHD SBIR/STTR funds are strongly encouraged to contact a program official prior to submitting any application in excess of the total award amounts listed. Confirm the full requirements in the official notice before applying.
Small Business Innovation Research (SBIR) Program (NIH, CDC, FDA) (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program encourages small businesses to develop innovative technologies in biomedical research, supported by a collaboration of the NIH, CDC, and FDA.
NIH Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) (Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This omnibus solicitation supports small business innovation research across a broad spectrum of topic areas, including those relevant to brain-computer interfaces. It is a parent announcement for SBIR grants where a clinical trial may be optional.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read articleCDC-RFA-EH-27-0074 posted as a forecast September 22, 2026: 6 expected awards at $750,000 to $900,000. That is flat funding against the expiring cycle — and the only proven way in is the consortium model Arizona used to bring three states under one award.
Read article